Patents by Inventor Michaela Bairlein

Michaela Bairlein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220117973
    Abstract: The present invention relates to the ATR kinase inhibitor, 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine, for use in the treatment of a hyper-proliferative disease, characterized in that it is administered in an amount of from 10 mg to 160 mg per day, particularly in an amount of 60 to 160 mg per day. The present invention also relates to a pharmaceutical composition comprising 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine in an amount of from 5 mg to 80 mg and at least one pharmaceutically acceptable excipient. The present invention also relates to a process for manufacturing said pharmaceutical composition.
    Type: Application
    Filed: February 6, 2020
    Publication date: April 21, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Dennis KRICKAU, Eleni LAGKADINOU, Antje Margret WENGNER, Michael KRAUSE, Peter SERNO, Michaela BAIRLEIN, Gary WILKINSON, Siobhan WATTERS, Pardis ASSI
  • Patent number: 11149018
    Abstract: The present application relates to novel substituted N-arylethyl-2-aminoquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 19, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut Beck, Raimund Kast, Mark Meininghaus, Chantal Fuerstner, Timo Stellfeld, Clemens-Jeremias Von Buehler, Lisa Dietz, Michaela Bairlein, Johanna Anlahr, Hannah Joerissen, Peter Hauff, Joerg Mueller, Karoline Droebner, Jens Nagel
  • Patent number: 11136296
    Abstract: The present application relates to novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 5, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Hartmut Beck, Raimund Kast, Mark Meininghaus, Lisa Dietz, Chantal Fuerstner, Timo Stellfeld, Sonja Anlauf, Clemens-Jeremias Von Buehler, Michaela Bairlein, Johanna Anlahr, Uwe Muenster, Carsten Terjung, Hannah Joerissen, Peter Hauff, Joerg Mueller, Karoline Droebner, Jens Nagel
  • Publication number: 20200157073
    Abstract: The present application relates to novel substituted N-arylethyl-2-aminoquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
    Type: Application
    Filed: April 4, 2018
    Publication date: May 21, 2020
    Inventors: Hartmut BECK, Raimund KAST, Mark MEININGHAUS, Chantal FUERSTNER, Timo STELLFELD, Clemens-Jeremias VON BUEHLER, Lisa DIETZ, Michaela BAIRLEIN, Johanna ANLAHR, Hannah JOERISSEN, Peter HAUFF, Joerg MUELLER, Karoline DROEBNER, Jens NAGEL
  • Publication number: 20200031775
    Abstract: The present application relates to novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
    Type: Application
    Filed: April 4, 2018
    Publication date: January 30, 2020
    Inventors: Hartmut BECK, Raimund KAST, Mark MEININGHAUS, Lisa DIETZ, Chantal FUERSTNER, Timo STELLFELD, Sonja ANLAUF, Clemens-Jeremias VON BUEHLER, Michaela BAIRLEIN, Johanna ANLAHR, Uwe MUENSTER, Carsten TERJUNG, Hannah JOERISSEN, Peter HAUFF, Joerg MUELLER, Karoline DROEBNER, Jens NAGEL
  • Publication number: 20180148418
    Abstract: The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredient.
    Type: Application
    Filed: May 2, 2016
    Publication date: May 31, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Knut EIS, Jens ACKERSTAFF, Sarah WAGNER, Philipp BUCHGRABER, Detlev SÜLZLE, Simon HOLTON, Eckhard BENDER, Volkhart LI, Ningshu LIU, Franziska SIEGEL, Philip LIENAU, Michaela BAIRLEIN, Franz VON NUSSBAUM, Simon Anthony HERBERT, Marcus KOPPITZ
  • Patent number: 9884063
    Abstract: The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 6, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Knut Eis, Jens Ackerstaff, Sarah Wagner, Daniel Basting, Stefan Golz, Eckhard Bender, Volkhart Min-Jian Li, Philip Lienau, Ningshu Liu, Franziska Siegel, Marcus Bauser, Detlev Sülzle, Simon Holton, Michaela Bairlein, Philipp Buchgraber, József Bálint
  • Publication number: 20170020886
    Abstract: The present invention relates to amido-substituted azole compounds of general formula (I), in which X1, X2, R1, R2, R4, R5, R7 and R8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: April 1, 2015
    Publication date: January 26, 2017
    Inventors: Knut EIS, Jens ACKERSTAFF, Sarah WAGNER, Daniel BASTING, Stefanü GOLZ, Eckhard BENDER, Volkhart Min-Jian LI, Philip LIENAU, Ningshu LIU, Franziska SIEGEL, Marcus BAUSER, Detlev SÜLZLE, Simon HOLTON, Michaela BAIRLEIN, Philipp BUCHGRABER, Jözsef BÁLINTT
  • Publication number: 20160151370
    Abstract: Compounds of formula (I) and their use as pharmaceutical.
    Type: Application
    Filed: June 17, 2014
    Publication date: June 2, 2016
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Marion HITCHCOCK, Anne MENGEL, Hans BRIEM, Ulrich LÜCKING, Gerhard SIEMEISTER, Wilhelm BONE, Jens SCHRÖDER, Michaela BAIRLEIN, Ursula MÖNNING, Michael BRÜNING
  • Patent number: 8959984
    Abstract: This invention relates to methods for the evaluation and/or quantification of the binding affinity of small molecules or other compounds to target components contained within an analyte, such as target proteins contained within the proteome of a cell or tissue.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: February 24, 2015
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Henrik Daub, Michaela Bairlein, Kirti Sharma, Klaus Godl, Andreas Tebbe, Christoph Weber
  • Publication number: 20100279891
    Abstract: This invention relates to methods for the evaluation and/or quantification of the binding affinity of small molecules or other compounds to target components contained within an analyte, such as target proteins contained within the proteome of a cell or tissue.
    Type: Application
    Filed: September 26, 2008
    Publication date: November 4, 2010
    Inventors: Henrik Daub, Michaela Bairlein, Kirti Sharma, Klaus Godl, Andreas Tebbe, Christoph Weber